Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.49 |
| ▸ | JAK1 | P23458 | 10/20 | 0.49 |
| ▸ | JAK3 | P52333 | 10/20 | 0.49 |
| ▸ | EIF2AK4 | Q9P2K8 | 3/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | BMX | P51813 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16824724 | 0.91 | JAK2 (0.44) | JAK2JAK1JAK3EIF2AK4ADORA2A | |
| SCHEMBL16824701 | 0.89 | JAK2 (0.53) | JAK2JAK1JAK3EIF2AK4 | |
| SCHEMBL2038350 | 0.89 | JAK2 (0.48) | JAK2JAK1JAK3EIF2AK4IRAK4 | |
| SCHEMBL2038353 | 0.89 | JAK2 (0.48) | JAK2JAK1JAK3EIF2AK4IRAK4 | |
| SCHEMBL2034661 | 0.89 | JAK2 (0.53) | JAK2JAK1JAK3 | |
| SCHEMBL2035018 | 0.89 | JAK2 (0.47) | JAK2JAK1JAK3EIF2AK4BTK | |
| SCHEMBL2035016 | 0.89 | JAK2 (0.47) | JAK2JAK1JAK3EIF2AK4BTK | |
| SCHEMBL2034659 | 0.89 | JAK2 (0.53) | JAK2JAK1JAK3 | |
| SCHEMBL2033334 | 0.85 | FLT3 (0.41) | JAK2JAK1JAK3EIF2AK4EGFR | |
| SCHEMBL16824789 | 0.85 | FLT3 (0.41) | JAK2JAK1JAK3EIF2AK4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015091531-A1 | IMIDAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2015-06-25 | — | — | WO | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| US-20110311583-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311583-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | SGMS1, SGMS2, PHOSPHO1 | JAK2 2232/4885JAK1 3572/4885JAK3 3498/4885 |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.